Genocea to Host Fourth Quarter and Year End 2014 Financial Results Conference Call & Webcast on February 12, 2015

CAMBRIDGE, Mass.--()--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on February 12, 2015 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2014. The presentation, hosted by Genocea President and Chief Executive Officer Chip Clark and Chief Financial Officer Jonathan Poole, will provide an update on the company's recent progress and upcoming milestones.

Interested participants and investors may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 69602121. To join the live webcast please visit the investor relations section of the Genocea website at http://ir.genocea.com.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.

About Genocea
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel T cell-enabled product candidates in Phase 2 development includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapies. For more information, please visit the company's website at www.genocea.com.

Contacts

For media:
Spectrum Science Communications
Megan Lustig, 202-955-6222
mlustig@spectrumscience.com
or
For investors:
Genocea Biosciences
Bob Farrell, 617-674-8261
bob.farrell@genocea.com

Genocea Biosciences, Inc.